Tazobactum%25252525252520piperacillin

# Piperacillin-Tazobactam ## Overview A combination of an extended-spectrum penicillin (piperacillin) and a beta-lactamase inhibitor (tazobactam). It provides coverage against many Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic bacteria. ## Primary Indications * Intra-abdominal infections (appendicitis, peritonitis) * Hospital-acquired and ventilator-associated pneumonia * Skin and skin structure infections * Gynecological infections (postpartum endometritis, pelvic inflammatory disease) * Febrile neutropenia (empiric therapy) ## Adult Dosing The standard dosage is **3.375 g to 4.5 g IV every 6 to 8 hours**. * **Serious infections:** 4.5 g (4 g piperacillin/0.5 g tazobactam) IV every 6 hours. * **Extended/Prolonged Infusion:** Often administered over 4 hours to maximize time above MIC for *Pseudomonas*. * **Maximum Dose:** 18 g (piperacillin component) per day. ## Pediatric Dosing * **Neonates (0–9 days):** 80 mg/kg (piperacillin component) every 12 hours. * **Neonates (10+ days):** 80 mg/kg (piperacillin component) every 8 hours. * **Children (≥9 months to ≤12 years):** 80–100 mg/kg/dose every 8 hours (maximum 4 g piperacillin per dose). * *Note: Dosing depends heavily on institutional protocols and the severity of infection.* ## Dose Adjustments * **Renal Impairment:** Requires reduction based on Creatinine Clearance (CrCl). * **CrCl 20–40 mL/min:** 2.25 g to 3.375 g every 6–8 hours. * **CrCl <20 mL/min:** 2.25 g every 8 hours. * **Hemodialysis:** Max 2.25 g every 8 hours, with an additional 0.75 g after dialysis. * **Hepatic Impairment:** No standard adjustment required, but monitor closely. ## Contraindications * Known hypersensitivity to piperacillin, tazobactam, or any beta-lactam (penicillins, cephalosporins, carbapenems) due to potential cross-reactivity. * History of severe allergic reactions (anaphylaxis) to any beta-lactam. ## Adverse Effects * **Common:** Diarrhea, constipation, nausea, headache, insomnia. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), rash (including DRESS/SJS), interstitial nephritis, leukopenia/neutropenia (with prolonged use), and seizure activity (at high doses in patients with renal failure). ## Key Drug Interactions * **Aminoglycosides:** May result in inactivation of the aminoglycoside; space doses by at least 1 hour. * **Warfarin:** May increase anticoagulant effect due to altered gut flora or platelet inhibition. * **Methotrexate:** May decrease renal clearance, increasing risk of toxicity. * **Probenecid:** Increases serum concentrations of piperacillin. ## Monitoring * **Renal Function:** Monitor BUN and Serum Creatinine. * **CBC with Differential:** Monitor for leucopenia or eosinophilia during prolonged therapy. * **Electrolytes:** Monitor for hypernatremia or hypokalemia (each gram contains ~2.8 mEq sodium). * **Clinical Response:** Signs of infection resolution (fever, WBC count, cultures). ## Clinical Pearls * **Antibiotic Stewardship:** Not first-line for uncomplicated infections; reserve for broad-spectrum needs. * **Sodium Load:** Consider the sodium content in patients with heart failure or hypertension. * **Stability:** Once reconstituted, the solution is stable for limited timeframes; verify stability per facility policy. * **Infusion Time:** Extended infusion (e.g., 4-hour infusion) is increasingly preferred in critical care settings to optimize pharmacodynamics versus intermittent bolus. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult current institutional prescribing protocols, updated clinical guidelines (e.g., Sanford Guide, IDSA), and the official FDA-approved package insert before prescribing or administering medication.